Immune thrombocytopenia can present a multitude of clinical challenges for providers, patients, and families. In 2011, the American Society of Hematology released guideline recommendations for the management of this challenging pediatric condition.
Management of newly diagnosed patients, persistently thrombocytopenic patients, patients who are refractory to first-line therapies including a variety of therapies from observation to steroids, infusions, thrombopoietin receptor agonists, and even surgical intervention. However, despite an increase in the number of therapies available to treat patients with ITP, there are minimal data from RCTs to guide providers in the management of patients. Recently, a multidisciplinary guideline panel that included adult and pediatric clinical experts reviewed evidence frameworks and agreed on 21 recommendations covering the management of ITP. This session aims to guide the learner through the classification of thrombocytopenia in pediatric patients and describe first- and second-line therapies available to treat Immune Thrompcytopenia in pediatric patients and will include a thorough review of the American Society of Hematology 2019 guidelines for immune thrombocytopenia. 3. Review ASH 2019 guidelines for Immune Thrombocytopenia in pediatric patients.
- Career Development Event: Career Development Event: Your CV, Your Key to Professional Development (CDE)
- General Session: Gene Therapy and Gene Editing as a Treatment Option for Patients with Hemoglobinopathies (103)
- Clinical Pearls of Pediatric Brain Tumors for the Advanced Practice Nurse (222)
- Protect Your Professional Life: Beware of Predatory Publishers and Conferences (223)
- Adopt, Adapt, Advance: Utilizing Evidence Based Practice, Quality Improvement and Nursing Research to Transform Pediatric Hematology/Oncology Nursing Practice (224)
- Anne Harvey, DNP CPNP0.50
- CNE Hours: